Individualized Pharmaceutical-care for Inpatients With Cancer Pain

Impact of Individualized Pharmaceutical-care on Medication Adherence and Outcome of Cancer Pain in Opioid-tolerant Inpatients

The purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant inpatients

This study is a prospective multicenter randomized controlled study to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant inpatients.

Inclusion Criteria:

• Patients aged 18 years or older;
• Histologically confirmed solid tumor;
• Diagnosed chronic cancer pain;
• Opioid-tolerant patients;
• Overall survival is expected to be over 3 months;
• Karnofsky performance score≥50;
• Willing and able to comply with the protocol

Exclusion Criteria:

• Current pregnancy or breastfeeding;
• Patients diagnosed with non-cancer pain;
• Patients treated with patient-controlled analgesia;
• Patients with pathological fracture, gastrointestinal obstruction, severe infection, non-opioid related intractable constipation;
• Patients with mental disorder;
• Creatinine clearance rate <15mL/min;
• ALT or AST ≥ 10 fold of upper limit of normal value